NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.97 -0.03 (-0.04%) GOLD FUTURES
2,313.60 +2.60 (+0.11%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,329.02 +1,772.68 (+3.89%)
Harvard Bioscience, Inc. (HBIO)
After hours:
| Previous close | 3.8200 |
| Open | 3.8900 |
| Bid | 3.7600 x 100 |
| Ask | 3.9400 x 100 |
| Day's range | 3.7710 - 3.9100 |
| 52-week range | 3.4400 - 6.2800 |
| Volume | |
| Avg. volume | 93,529 |
| Market cap | 165.869M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.88 |
GlobeNewswireHarvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-onl
- GlobeNewswire
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million. Jim Green, Harvard Bioscience Chairman and CEO,
Simply Wall St.Investing in Harvard Bioscience (NASDAQ:HBIO) a year ago would have delivered you a 25% gain
It hasn't been the best quarter for Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shareholders, since the share price has...
